GlassScriptPhysician profile
Liliana Lara
NPI 1346059060
$1,551.88
in general payments reported to CMS, 2019-2025
20 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $306.11 | 2025 | Krystexxa, Repatha, Otezla |
| Glaxosmithkline, LLC. | $178.38 | 2025 | Benlysta, Trelegy Ellipta |
| Ucb, INC. | $163.07 | 2025 | Bimzelx |
| Abbvie INC. | $151.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $150.04 | 2025 | Airsupra, Saphnelo, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $112.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $85.27 | 2025 | |
| Mallinckrodt Hospital Products INC. | $80.35 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $78.26 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $48.25 | 2025 | Mounjaro, Jardiance |
| Sobi, INC | $31.39 | 2025 | |
| Corcept Therapeutics | $26.66 | 2025 | Korlym |
| Novo Nordisk INC | $21.73 | 2025 | Ozempic, Rybelsus |
| Radius Health, INC. | $21.51 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $21.10 | 2025 | Capvaxive, Gardasil 9 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.68 | 2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $17.81 | 2025 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $15.84 | 2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $13.85 | 2025 | Lupkynis |
| Phathom Pharmaceuticals, INC. | $10.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liliana Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.